TITUSVILLE, N.J., Nov. 17, 2017 /PRNewswire/ -- A new real-world analysis of adults with type 2 diabetes and established cardiovascular disease (CVD) shows adult patients who initiated therapy with INVOKANA®
Growth Capitalist (https://growthcapitalist.com/2017/11/new-real-world-analysis-shows-invokana-canagliflozin-and-other-sglt2-inhibitors-reduced-the-risk-of-death-and-cardiovascular-events-compared-to-other-diabetes-medicines/)
TITUSVILLE, N.J., Nov. 17, 2017 /PRNewswire/ -- A new real-world analysis of adults with type 2 diabetes and established cardiovascular disease (CVD) shows adult patients who initiated therapy with INVOKANA®